Company profile
Avalo Therapeutics, Inc.
NASDAQ:AVTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Quisovalimab | phase2 | — | 2 | completed, terminated |
| RISLENEMDAZ | phase2 | — | 2 | no active trials |
| CAMOTESKIMAB | phase1 | — | 2 | no active trials |
| OSI-027 | phase1 | — | 1 | withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04994002 | phase1 | withdrawn | 2021-09-03 | 2022-06-01 | Avalo Therapeutics, Inc. | A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations |
| NCT01941043 | phase2 | completed | 2013-11-01 | 2014-09-01 | Avalo Therapeutics, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment |
| NCT01579526 | phase1 | completed | 2012-04-01 | 2012-04-01 | Avalo Therapeutics, Inc. | A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers |
| NCT02459236 | phase2 | completed | 2015-06-01 | 2016-09-01 | Avalo Therapeutics, Inc. | A Study of Intermittent Doses of CERC-301 in MDD |
| NCT06603077 | phase2 | completed | 2024-09-16 | 2026-02-23 | Avalo Therapeutics, Inc. | A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa |
FDA applications (0)
No records yet.